Although both are predictive biomarkers for sensitivity to immune checkpoint blockade, TMB and PDL1 do not necessarily select for the same patients as illustrated by the fact that dual checkpoint blockade for NSCLC was beneficial with high TMB, irrespective of PDL1 status [60]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.